Teclison was founded with the vision of assembling leading scientists, advisors, and other leaders with significant pharmaceutical expertise to develop groundbreaking therapies for cancer. The company specializes in the development of innovative cancer medicines which induce tumor necrosis and enhance anti-tumor immunity for long-term cancer remission. The company’s drug is designed to treat any solid tumor with a predilection for liver metastasis, including hepatocellular carcinoma and metastatic colorectal cancer first, and expanding to other solid tumors with liver metastasis. Teclison’s novel approach is a first-in-class hypoxia-activating agent which achieves long-term remission in hard-to-treat cancer cell, cancer stem cells and tumor-promoting macrophage targets by creating high local concentration of its compound and producing profound hypoxia exclusively within the tumor
Company Details
- Employees
- 9
- Address
- 26 Park Street, Suite 2100, Montclair,nj 07042,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.teclison.com/
- Keywords
- Oncology.
- HQ
- Montclair, NJ
Teclison Questions
Teclison's website is https://www.teclison.com/
Teclison's LinkedIn profile is https://www.linkedin.com/company/teclison
Teclison has
9 employees.
View email and phone details for 9
employees at Teclison.
Teclison's industry is
Biotechnology Research
Teclison's top competitors are
Sorrento Therapeutics, Inc.,
Luxe Digitalpulsemedia,
Humanate Inc.,
Nemagen Discoveries,
Zena Therapeutics Inc.,
Theradex Oncology,
Insmed Incorporated,
Acutis Biosciences,
Innocube Biosciences Inc.,
Cugene Inc..
Teclison's categories are Biotechnology Research
